Myeloma Collection | Blood Cancer Discovery | American Association for Cancer Research
The Blood Cancer Discovery editors proudly present this collection of impactful myeloma articles that have been published in the Journal.
Related Articles
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma
Abstract. Polatuzumab Vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V…
Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Abstract. Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The…
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma
Abstract. Polatuzumab Vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V…
Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
A multi-cohort, pan-cancer analysis uncovered racial disparities in cancer genomes between Asian and White populations and elucidated pairwise relationships of driver alterations, providing valuable resources…
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to…
RAS G12C Inhibitors: Three Birds with One Stone
Summary:. In this issue, Rubinson, Tanaka, and colleagues demonstrate that differences among G12C inhibitors rely on their ability to covalently bind not only G12C mutant…
Highlighted research articles
In this study, Rubinson, Tanaka, and colleagues reveal that a subset of switch-II pocket-binding KRASG12C inhibitors can target all RASG12C proteins. In contrast to KRASG12C-specific…
Enhanced Molecular Response in Myeloproliferative Neoplasms with Complete JAK2V617F Inhibition
Summary:. Dunbar, Bowman, and colleagues present here a novel genetic mouse model with inducible and reversible expression of the JAK2V617F mutation in the endogenous locus.…
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
Abstract. Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led…
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
Abstract. Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led…